Appointments

 
Premas Biotech announced the appointment of Saumen Chakraborty to the Premas Biotech Board of Directors. “I am delighted to join the Premas Biotech Board of Directors. I am quite excited with the potential of Premas Biotech with its outstanding capabilities,” said Saumen Chakraborty.<br />
<br />
Saumen Chakraborty is the Managing Director of Samarjita Management Consultancy Private Limited. He retired as the President and Chief Financial Officer of Dr Reddy’s in 2020 and served as an Advisor to them for the next year. He has over 37 years of experience in both strategic and operational aspects of management and has played a significant role in the evolution of Dr Reddy´s as a global pharmaceutical company in India. He served at the CXO level in multiple areas ranging from global finance, legal & compliance, digital & process excellence, global HR, quality, and corporate & global generics operations at Dr Reddy´s.<br />
<br />
As the Chief Financial Officer, Saumen has been awarded the "India s Best CFO" by IMA, 2016 & "India s Best CFO with Exemplary All Round Performance" in the "5th Annual Business Today – YES Bank BEST CFO Awards" 2014. He was also the recipient of the ‘Best Performing CFO in the Healthcare Sector’ award for 2007 by CNBC TV-18. Other key portfolios and initiatives Saumen has handled in his current and previous roles at CMC, C-DOT, Eicher, Tecumseh and Dr Reddy’s include manufacturing, sourcing, customer service, Quality, Consulting, HR and IT.<br />
 <br />
Saumen is a postgraduate in management from IIM, Ahmedabad and an executive fellow in management from ISB, Hyderabad. His doctoral dissertation at ISB was ‘How to do dynamic resource allocation in the generic pharmaceutical industry?’. <br />
Mr Avijit Das, Founder Chairman, Premas Biotech said "Saumen s deep experience in global Pharma businesses with strong commercial and business insight will be invaluable to Premas as we grow our business and pursue our mission to become a protein therapeutics and vaccine partner.”<br />
<br />
On the other hand, Dr Prabuddha Kundu, Co-founder and Managing Director, Premas Biotech  expressed his satisfaction with the appointment “Saumen’s understanding of the Global Health and Pharma Business would be of immense value to Premas Biotech as we scale up and grow into different business segments along with delivering novel therapies and vaccines.”

Saumen Chakraborty

PREMAS BIOTECH, Member Board of Directors Premas Biotech announced the appointment of Saumen Chakraborty to the Premas Biotech Board of Directors. “I am delighted to join the Premas Biotech Board of Directors. I am quite excited with the potential of Premas Biotech with its outstanding capabilities,” said Saumen Chakraborty.

Saumen Chakra...

Read more >
Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, announced that Silvia Steyrer-Gruber has been named as Chief Executive Officer.<br />
<br />
Silvia brings strong international leadership experience to Coriolis. In her previous role as Managing Director Europe at Exeltis (part of the Insud Pharma Group), she was responsible for the European branded pharmaceutical business of the family-owned Spanish Multinational Healthcare Group. Prior to that, Silvia served at Baxter, Kwizda Pharma and Serono in senior roles, and gained more than 25 years of experience in Biotech, Vaccine and Pharmaceutical companies.<br />
<br />
Silvia said ?it is a highly exciting time to join the great team at Coriolis Pharma, as the company is set to further expedite its growth and internationalization over the next years. By innovating formulation for its clients, Coriolis Pharma contributes to bringing new therapeutics to patients, many of them in areas of high unmet medical need. I was attracted by the strong focus on scientific innovation, coupled with a very high client orientation and, not last, the wish to even further shape an outstanding place to work for the own Coriolis team.?<br />
<br />
Dr. Michael Wiggenhorn and Thomas Wiggenhorn co-founded Coriolis Pharma in 2008 in order to develop a leading specialty service provider in the area of formulation innovation and have grown the company to its current strong position. Michael and Thomas will now step up to the Board of Directors, also focusing on strategic projects for the further growth of Coriolis Pharma.<br />
<br />
?The appointment of Silvia marks the next step in our growth journey for Coriolis Pharma,? said Thomas Wiggenhorn. ?Under her leadership, the management team of Coriolis will now develop the future growth concept for geographical expansion as well as the expansion of our service offerings.?<br />
<br />
?Our scientific expertise will remain the cornerstone of our client collaboration for the future,? said Dr. Michael Wiggenhorn. ?The recent announcements of new members for the Scientific Advisory Board as well as the partnership with U-Medico in Japan emphasize this strongly.?<br />
<br />
Silvia will continue to work in close collaboration with Michael and Thomas.

Silvia Steyrer-Grube

Coriolis Pharma, Chief Executive Officer, CEO Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, announced that Silvia Steyrer-Gruber has been named as Chief Executive Officer.

Silvia brings strong international leadership experience to Coriolis. In her...

Read more >
 
 
 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members